SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT (TM) FOR ADVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A First and only FDA-cleared PK dosing software to support ...

Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...

A post-hoc analysis has identified an interrelation between peak levels of factor VIII (:FVIII) in a patient’s body in the first few hours after infusion and the efficiency of prophylaxis treatment in ...

June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...

MyPKFiT is intended for use by healthcare professionals who are familiar with hemophilia care Shire has announced the availability of myPKFit, a new pharmacokinetic (PK) dosing software for use with ...

LONDON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the European Medicines Agency has authorized an update to the Summary of Product Characteristics (SmPC) for Baxter's ...

DEERFIELD, Ill., Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today presented additional efficacy and safety data from the Phase III ...

Biogen (BIIB) is launching its first drugs for the treatment of hemophilia this year, challenging Baxter's (BAX) long-held dominance. Improving treatment Of course, Baxter isn't about to just hand ...

While competition is around the corner for Advate, Baxter's (BAX) highly profitable hemophilia A product, we think this diversified health-care firm's competitive advantages remain strong. Baxter's ...

Baxter International ( BAX) presented encouraging data from the Advate [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] prophylaxis study at the International Society on Thrombosis ...